Medicines

In the fight to improve global health, we focus on six disease areas that have significant impact on people’s lives in the UK.

More focus, greater impact

We’ve streamlined our work by developing new innovative medicines for a core group of illnesses: cancer, gastro-intestinal, infection, respiratory and inflammation, neuroscience and cardiovascular.

In the UK, we invest around £1 billion each year in research and development, and through collaborations with the healthcare industry and its patients, we’re developing even more targeted medicines.


Cardiovascular & Diabetes

Cardiovascular diseases, including coronary heart disease and acute coronary syndrome, kill one in three people in the UK each year1. It is estimated that around 10% of the NHS budget is spent on diabetes2


Gastrointestinal

In the West (i.e. Europe and North America) between 10-20% of adults suffer from gastro-oesophageal reflux disease (GORD)3.


Infection

Increasingly resistant to antibiotics, many infectious diseases continue to be a risk to global health.


Oncology

UK cancer rates are expected to rise 45% by 20304, making our work in this area increasingly important.

Neuroscience

Our innovations in neuroscience include anesthetic treatments and medicines for mental illness and headaches disorders.


Respiratory & Inflammation

Over 5.4 million people in the UK have asthma5; so developing new treatments for this and other respiratory diseases is vital to improving lives.



For information about our medicines if you are a healthcare professional, visit our UK healthcare professionals resource website www.simply4doctors.co.uk


For information about ordering Astrazeneca's products if you are a pharmacist, visit our medicines supply site www.azsupply.co.uk